Sanofi to Acquire Blueprint Medicines to Expand Rare Immunology Pipeline

Sanofi Acquires Translate Bio in $3.2 Billion Deal

August 3, 2021

Biotechnology

Sanofi SA has entered into a definitive agreement to acquire all outstanding shares of clinical-stage mRNA therapeutics company Translate Bio for about $3.2 billion, or $38.00 per share in cash. The acquisition is intended to accelerate Sanofi’s application of messenger RNA (mRNA) to develop therapeutics and vaccines, building on an existing mRNA collaboration.

Biogen Acquires Human Immunology Biosciences for up to $1.8B

May 22, 2024

Biotechnology

Biogen Inc. has agreed to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in milestone payments, in a deal valued at up to $1.8 billion. The acquisition adds HI-Bio's lead asset felzartamab, an investigational anti-CD38 antibody with Phase 2 data in multiple renal immune-mediated diseases, to Biogen's immunology and rare-disease development capabilities.

Mirum Pharmaceuticals Acquires Bluejay Therapeutics

January 26, 2026

Pharmaceuticals

Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, adding brelovitug — a late‑stage monoclonal antibody for chronic hepatitis delta virus (HDV) — to its rare liver disease pipeline. The deal gives Mirum worldwide rights to the AZURE Phase 3 program and includes a combination of cash and Mirum common stock with potential sales‑based milestone payments; Mirum also raised approximately $268.5M in concurrent financing to support development and commercialization.

Sanofi to Acquire DR-0201 Program from Dren Bio

March 20, 2025

Biotechnology

Sanofi has agreed to acquire DR-0201, a CD20-directed bispecific myeloid cell engager, through purchase of Dren Bio’s affiliate Dren-0201 for an upfront $600 million and up to $1.3 billion in milestone payments. The deal, aimed at broadening Sanofi’s immunology pipeline and advancing deep B-cell depletion approaches, is expected to close in Q2 2025 subject to regulatory approvals; Dren Bio will continue to operate independently to advance its broader pipeline.

Ipsen Acquires Albireo Pharma

January 9, 2023

Biotechnology

Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.

Sanofi to Acquire Provention Bio for $2.9 Billion

March 13, 2023

Pharmaceuticals

Sanofi has entered into an agreement to acquire Provention Bio for $25.00 per share in cash, valuing the deal at approximately $2.9 billion. The transaction will be implemented via a cash tender offer followed by a merger, with completion expected in the second quarter of 2023 subject to customary closing conditions.